Research Professor, Department of Biomedical Sciences
Contact Information
Email:Biosketch
Jerry Colca, PhD is President and Chief Scientific Officer, and a co-founder of MSDC. He is a widely recognized expert in the pathophysiology of insulin resistance and the pharmacological mechanisms of action of insulin sensitizing drugs. He has dedicated his career to studying the endocrine control of metabolism as it relates to diabetes and has been focused on insulin sensitizers from the early days of their discovery, especially on the safety and pharmacology of pioglitazone. His long-held commitment to treating and preventing diabetes underpins the mission of MSDC, which he co-founded in 2006. This vision forms the basis for the company’s research and development into compounds that may treat the root causes of age-related metabolic diseases like diabetes and Alzheimer’s disease. Under his leadership, MSDC is advancing its discovery of a novel mitochondrial protein complex that is believed to be the mechanism through which insulin sensitizing drugs achieve effective glucose control.
In 1984, Dr. Colca joined The Upjohn Company to study the mechanism of action of the thiazolidinediones and served as project leader for the selection and early development of pioglitazone hydrochloride (Actos®), one of the most successful insulin sensitizers ever developed for the treatment of diabetes. Following The Upjohn Company’s decision to exit the diabetes field in 1993, Dr. Colca continued his metabolic disease research with the company through its mergers with Pharmacia, Monsanto-Searle, and Pfizer, building a new diabetes drug discovery capability in Sweden for Pharmacia, and developing a new target discovery effort in St. Louis for Pfizer.
Dr. Colca has published widely on the mechanism of action of insulin sensitizers, and is the author of more than 80 publications, chapters and presentations. He is a section editor for Expert Opinion in Investigational Drugs and is a member of numerous organizations including American Diabetes Association, American Society for Biochemistry and Molecular Biology, American Association for the Advancement of Science, and The New York Academy of Sciences.
Dr. Colca received a BS in biology and an MS and PhD in physiology and biochemistry from the University of Houston, where his early studies focused on the regulation of the secretion of pancreatic hormones. His post-doctoral fellowship in the Department of Pathology at Washington University, School of Medicine in St. Louis concentrated on the biochemistry of isolated pancreatic islets and the study of stimulus-secretion coupling in the control of metabolism.
-
Education and Training
- Postdoctoral Research Fellowship 2005, Genomics and Biotechnology, Pfizer St. Louis
- Postdoctoral Research Fellowship 1984, Juvenile Diabetes, Washington University in St. Louis
- PhD 1980, Physiology/Biochemistry, University of Houston
- MS 1975, Physiology/Biochemistry, University of Houston
- BS 1972, General Biology, University of Houston
-
Publications
Colca J.R., McCommis K.S. Metabolic dysfunction and insulin sensitizers in acute and chronic disease Expert Opinion on Investigational Drugs. 2025
Colca J.R., Tanis S.P., Kletzien R.F., Finck B.N. Insulin sensitizers in 2023: lessons learned and new avenues for investigation Expert Opinion on Investigational Drugs. 2023;32:803-811.
Ferguson D., Eichler S.J., Yiew N.K.H., Colca J.R., Cho K., Patti G.J., Shew T.M., Lutkewitte A.J., Mukherjee S., McCommis K.S., Niemi N.M., Finck B.N. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism Molecular Metabolism. 2023;70
Zhu B., Wei X., Narasimhan H., Qian W., Zhang R., Cheon I.S., Wu Y., Li C., Jones R.G., Kaplan M.H., Vassallo R.A., Braciale T.J., Somerville L., Colca J.R., Pandey A., Jackson P.E.H., Mann B.J., Krawczyk C.M., Sturek J.M., Sun J. Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19 Science Immunology. 2023;8
Colca J.R., Finck B.N. Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches Frontiers in Molecular Biosciences. 2022;9
Colca J.R., Scherer P.E. The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease Molecular Metabolism. 2022;55
Mallet D., Goutaudier R., Barbier E.L., Carnicella S., Colca J.R., Fauvelle F., Boulet S. Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson’s Disease Molecular Neurobiology. 2022;59:6170-6182.
Kamm D.R., Pyles K.D., Sharpe M.C., Healy L.N., Colca J.R., McCommis K.S. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide Journal of Biological Chemistry. 2021;296
Bardova K., Funda J., Pohl R., Cajka T., Hensler M., Kuda O., Janovska P., Adamcova K., Irodenko I., Lenkova L., Zouhar P., Horakova O., Flachs P., Rossmeisl M., Colca J., Kopecky J. Additive effects of omega-3 fatty acids and thiazolidinediones in mice fed a high-fat diet: Triacylglycerol/fatty acid cycling in adipose tissue Nutrients. 2020;12:1-23.
Colca J. NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root Expert Opinion on Investigational Drugs. 2020;29:191-196.
Davison B.A., Harrison S.A., Cotter G., Alkhouri N., Sanyal A., Edwards C., Colca J.R., Iwashita J., Koch G.G., Dittrich H.C. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials Journal of Hepatology. 2020;73:1322-1332.
Harrison S.A., Alkhouri N., Davison B.A., Sanyal A., Edwards C., Colca J.R., Lee B.H., Loomba R., Cusi K., Kolterman O., Cotter G., Dittrich H.C. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study Journal of Hepatology. 2020;72:613-626.
Peelaerts W., Bergkvist L., George S., Johnson M., Meyerdirk L., Schulz E., Steiner J.A., Madaj Z., Ma J., Becker K., Nilsson K.P.R., Colca J.R., Brundin P. Inhibiting the mitochondrial pyruvate carrier does not amelio-rate synucleinopathy in the absence of inflammation or metabolic deficits Free Neuropathology. 2020;1
Tanis S.P., Colca J.R., Parker T.T., Artman G.D., Larsen S.D., Gadwood R.C., Zeller J.R. The development of improved syntheses of PPARγ-sparing, insulin sensitizing thiazolidinedione-ketones Tetrahedron Letters. 2019;60
Colca J.R., McDonald W.G., Adams W. Msdc-0602k, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis Expert Opinion on Investigational Drugs. 2018;27(7):631-636.
McCommis K., Colca J., Finck B. Reply Hepatology. 2018;67(5):2055-2056.
Quansah E., Peelaerts W., Langston J.W., Simon D.K., Colca J., Brundin P. Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration Molecular Neurodegeneration. 2018;13(1)
Tanis S.P., Colca J.R., Parker T.T., Artman G.D., Larsen S.D., McDonald W.G., Gadwood R.C., Kletzien R.F., Zeller J.B., Lee P.H., Adams W. PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development Bioorganic and Medicinal Chemistry. 2018;26(22):5870-5884.
Colca J.R., McDonald W.G., McCommis K.S., Finck B.N. Treating fatty liver disease by modulating mitochondrial pyruvate metabolism Hepatology Communications. 2017;1:193-197.
McCommis K.S., Hodges W.T., Brunt E., Nalbantoglu I., McDonald W.G., Holley C., Fujiwara H., Schaffer J.E., Colca J.R., Finck B.N. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis Hepatology. 2017;65(5):1543-1556.
Vigueira P., McCommis K.S., Hodges W.T., Schweitzer G.G., Cole S.L., Oonthonpan L., Taylor E.B., McDonald W.G., Kletzien R.F., Colca J.R., Finck B.N. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism Experimental Physiology. 2017;102(8):985-999.
Ghosh A., Tyson T., George S., Hildebrandt E.N., Steiner J.A., Madaj Z., Schulz E., MacHiela E., McDonald W.G., Galvis M.L.E., Kordower J.H., Van Raamsdonk J.M., Colca J.R., Brundin P. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease Science Translational Medicine. 2016;8(368)
Boros L.G., Beger R.D., Meuillet E.J., Colca J.R., Szalma S., Thompson P., Dux L., Farkas G., Somlyai G. Targeted <sup>13</sup>C-labeled tracer fate associations for drug efficacy testing in cancer Tumor Cell Metabolism: Pathways, Regulation and Biology. 2015:349-372.
Colca J. Discontinued drug therapies to treat diabetes in 2014 Expert Opinion on Investigational Drugs. 2015;24(9):1241-1245.
Colca J. The TZD insulin sensitizer clue provides a new route into diabetes drug discovery Expert Opinion on Drug Discovery. 2015;10(12):1259-1270.
Fukunaga T., Zou W., Rohatgi N., Colca J.R., Teitelbaum S.L. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss Journal of Bone and Mineral Research. 2015;30(3):508-515.
McCommis K.S., Chen Z., Fu X., McDonald W.G., Colca J.R., Kletzien R.F., Burgess S.C., Finck B.N. Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling Cell Metabolism. 2015;22(4):682-694.
Colca J., Mcdonald W., Kletzien R. Mitochondrial target of thiazolidinediones Diabetes, Obesity and Metabolism. 2014;16(11):1048-1054.
Colca J., Tanis S., McDonald W., Kletzien R. Insulin sensitizers in 2013: New insights for the development of novel therapeutic agents to treat metabolic diseases Expert Opinion on Investigational Drugs. 2014;23(1):1-7.
Shah R., Matthews D., Andrews R., Capuano A., Fleischman D., VanderLugt J., Colca J. An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease Current Alzheimer Research. 2014;11(6):564-573.
Vigueira P., McCommis K.S., Schweitzer G.G., Remedi M.S., Chambers K.T., Fu X., McDonald W.G., Cole S.L., Colca J.R., Kletzien R.F., Burgess S.C., Finck B.N. Mitochondrial Pyruvate Carrier 2 Hypomorphism in Mice Leads to Defects in Glucose-Stimulated Insulin Secretion Cell Reports. 2014;7(6):2042-2053.
Colca J. Discontinued drugs in 2012: Endocrine and metabolic Expert Opinion on Investigational Drugs. 2013;22(10):1305-1313.
Colca J. Extend data exclusivity to save drug development Science. 2013;339(6118):393.
Colca J.R., McDonald W.G., Cavey G.S., Cole S.L., Holewa D., Brightwell-Conrad A.S., Wolfe C.L., Wheeler J.S., Coulter K.R., Kilkuskie P.M., Gracheva E., Korshunova Y., Trusgnich M., Karr R., Wiley S.E., Divakaruni A.S., Murphy A.N., Vigueira P.A., Finck B.N., Kletzien R.F. Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)-Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins PLoS ONE. 2013;8(5)
Colca J.R., Vanderlugt J.T., Adams W., Shashlo A., McDonald W.G., Liang J., Zhou R., Orloff D.G. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer Clinical Pharmacology and Therapeutics. 2013;93(4):352-359.
Divakaruni A.S., Wiley S.E., Rogers G.W., Andreyev A.Y., Petrosyan S., Loviscach M., Wall E.A., Yadava N., Heuck A.P., Ferrick D.A., Henry R.R., McDonald W.G., Colca J.R., Simon M., Ciaraldi T.P., Murphy A.N. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier Proceedings of the National Academy of Sciences of the United States of America. 2013;110(14):5422-5427.
Rohatgi N., Aly H., Marshall C.A., McDonald W.G., Kletzien R.F., Colca J.R., McDaniel M.L. Novel Insulin Sensitizer Modulates Nutrient Sensing Pathways and Maintains β-Cell Phenotype in Human Islets PLoS ONE. 2013;8(5)
Chen Z., Vigueira P.A., Chambers K.T., Hall A.M., Mitra M.S., Qi N., McDonald W.G., Colca J.R., Kletzien R.F., Finck B.N. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione Journal of Biological Chemistry. 2012;287(28):23537-23548.
Colca J. Discontinued drugs 2011: Endocrine and metabolic Expert Opinion on Investigational Drugs. 2012;21(11):1619-1624.
Colca J., Feinstein D. Altering Mitochondrial Dysfunction as an Approach to Treating Alzheimer's Disease Advances in Pharmacology. 2012;64:155-176.
Colca J.R. Discontinued drugs in 2008: Endocrine and metabolic Expert Opinion on Investigational Drugs. 2009;18(9):1243-1255.
Colca J.R., Kletzien R.F. Current and emerging strategies for treating dyslipidemia and macrovascular disease. Advances in pharmacology (San Diego, Calif.). 2009;57:237-251.
Colca J. Discontinued drug in 2007: Renal, endocrine and metabolic drugs Expert Opinion on Investigational Drugs. 2008;17(11):1641-1650.
Bolten C.W., Payne M.A., Mcdonald W.G., Blanner P.M., Chott R.C., Ghosh S., Arhancet G.B., Staten N., Gulve E.A., Sullivan P., Hromockyj A.E., Colca J.R. Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat Diabetes and Vascular Disease Research. 2007;4(2):117-123.
Colca J. 67th Annual Meeting of the American Diabetes Association. 22 - 26 June 2007, Chicago, USA Expert Opinion on Investigational Drugs. 2007;16(10):1735-1739.
Colca J. Discontinued drugs in 2005: Endocrine and metabolic Expert Opinion on Investigational Drugs. 2007;16(2):129-136.
Colca J. Discontinued drugs in 2006: Renal, endocrine and metabolic drugs Expert Opinion on Investigational Drugs. 2007;16(10):1517-1523.
Colca J. Editorial overview: Future directions for insulin sensitizers in disease prevention Current Opinion in Investigational Drugs. 2007;8(9):707-710.
Leach K., Swaney S., Colca J., McDonald W., Blinn J., Thomasco L., Gadwood R., Shinabarger D., Xiong L., Mankin A. The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human Mitochondria Molecular Cell. 2007;26(3):393-402.
Colca J., Kletzien R. What has prevented the expansion of insulin sensitisers? Expert Opinion on Investigational Drugs. 2006;15(3):205-210.
Colca J.R. Insulin sensitizers may prevent metabolic inflammation Biochemical Pharmacology. 2006;72(2):125-131.
Harrigan G., Colca J., Szalma S., Boros L. PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: A comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells Metabolomics. 2006;2(1):21-29.
Colca J., Harrigan G. Photo-affinity labeling strategies in identifying the protein ligands of bioactive small molecules: Examples of targeted synthesis of drug analog photoprobes Combinatorial Chemistry and High Throughput Screening. 2004;7(7):699-704.
Colca J.R., McDonald W.G., Waldon D.J., Leone J.W., Lull J.M., Bannow C.A., Lund E.T., Mathews W.R. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe American Journal of Physiology - Endocrinology and Metabolism. 2004;286(2 49-2)
Colca J.R., McDonald W.G., Waldon D.J., Thomasco L.M., Gadwood R.C., Lund E.T., Cavey G.S., Mathews W.R., Adams L.D., Cecil E.T., Pearson J.D., Bock J.H., Mott J.E., Shinabarger D.L., Xiong L., Mankin A.S. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics Journal of Biological Chemistry. 2003;278(24):21972-21979.
Meurer J., Colca J., Burton P., Elhammer A. Properties of native and in vitro glycosylated forms of the glucagon- like peptide-1 receptor antagonist exendin(9-39) Metabolism: Clinical and Experimental. 1999;48(6):716-724.
Colca J. 58th Annual Meeting of the American Diabetes Association, June 13-16, 1998, Chicago, IL, USA Expert Opinion on Investigational Drugs. 1998;7(8):1341-1343.
Colca J. Oncologic, Endocrine and Metabolic. 57th American Diabetes Association Annual Meeting Expert Opinion on Investigational Drugs. 1997;6(8):1113-1115.
Colca J.R. 56th annual meeting of the American Diabetes Association, San Francisco, USA, 8-11 July 1996 Expert Opinion on Investigational Drugs. 1996;5(8):1059-1061.
Kurowski T., Saha A.K., Cunningham B.A., Holbert R.I., Colca J.R., Corkey B.E., Ruderman N.B. Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: Effects of pioglitazone Metabolism: Clinical and Experimental. 1996;45(4):519-525.
Tanis S., Parker T., Colca J., Fisher R., Kletzein R. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone Journal of Medicinal Chemistry. 1996;39(26):5053-5063.
Bonini J.A., Colca J., Hofmann C. Altered expression of insulin signaling components in streptozotocin-treated rats Biochemical and Biophysical Research Communications. 1995;212(3):933-938.
Bonini J.A., Colca J.R., Dailey C., White M., Hofmann C. Compensatory alterations for insulin signal transduction and glucose transport in insulin-resistant diabetes American Journal of Physiology - Endocrinology and Metabolism. 1995;269(4 32-4)
Braithwaite S.S., Palazuk B., Colca J.R., Edwards C.W., Hofmann C. Reduced expression of hexokinase II in insulin-resistant diabetes Diabetes. 1995;44(1):43-48.
Colca J. Monthly update oncologic, endocrine & metabolic: Insulin sensitiser drugs in development for the treatment of diabetes Expert Opinion on Investigational Drugs. 1995;4(1):27-29.
Hofmann C., Lorenz K., Williams D., Palazuk B., Colca J. Insulin sensitization in diabetic rat liver by an antihyperglycemic agent Metabolism. 1995;44(3):384-389.
Colca J. Potential antidiabetic drugs affecting the sensitivity of tissues to insulin Expert Opinion on Investigational Drugs. 1994;3(8):857-860.
Colca J. Section editor, oncologic, endocrine and metabolic: Editorial commentary Expert Opinion on Investigational Drugs. 1994;3(12):1231-1232.
Colca J., Hillman R. Potential peptide targets in NIDDM Expert Opinion on Investigational Drugs. 1994;3(1):37-39.
Hofmann C., Lorenz K., Braithwaite S., Colca J., Palazuk B., Hotamisligil G., Spiegelman B. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance Endocrinology. 1994;134(1):264-270.
Hofmann C., Lorenz K., Braithwaite S., Colca J., Palazuk B., Hotamisligil G., Spiegelman B. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance Endocrinology. 1994;134(1):264-270.
Norling L.L., Colca J.R., Kelly P.T., McDaniel M.L., Landt M. Activation of calcium and calmodulin dependent protein kinase II during stimulation of insulin secretion Cell Calcium. 1994;16(2):137-150.
Saha A., Kurowski T., Colca J., Ruderman N. Lipid abnormalities in tissues of the KKAy mouse: Effects of pioglitazone on malonyl-CoA and diacylglycerol AM.J.PHYSIOL.. 1994;267(1 part 1)
Saha A.K., Kurowski T.G., Colca J.R., Ruderman N.B. Lipid abnormalities in tissues of the KKA(y) mouse: Effects of pioglitazone on malonyl-CoA and diacylglycerol American Journal of Physiology - Endocrinology and Metabolism. 1994;267(1 30-1)
Towns R., Kostyo J., Colca J. Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth. Endocrinology. 1994;134(2):608-613.
Towns R., Kostyo J.L., Colca J.R. Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth Endocrinology. 1994;134(2):608-613.
Castle C., Colca J., Melchior G. Lipoprotein profile characterization of the KKA<sup>y</sup> mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone Arteriosclerosis, Thrombosis, and Vascular Biology. 1993;13(2):302-309.
Colca J., Tanis S. Recent Advances in the Discovery and Development of Potential Antidiabetic Agents Annual Reports in Medicinal Chemistry. 1992;27(C):219-226.
Hofmann C., Colca J. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers Diabetes Care. 1992;15(8):1075-1079.
Hofmann C.A., Edwards C.W., Hillman R.M., Colca J.R. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression Endocrinology. 1992;130(2):735-740.
Landt M., Easom R.A., Colca J.R., Wolf B.A., Turk J., Mills L.A., McDaniel M.L. Parallel effects of arachidonic acid on insulin secretion, calmodulin-dependent protein kinase activity and protein kinase C activity in pancreatic islets Cell Calcium. 1992;13(3):163-172.
Colca J., Dailey C., Palazuk B., Hillman R., Dinh D., Melchior G., Spilman C. Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats Diabetes. 1991;40(12):1669-1674.
Hofmann C., Lorenz K., Colca J.R. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone Endocrinology. 1991;129(4):1915-1925.
Krogstad D.J., Sutera S.P., Marvel J.S., Gluzman I.Y., Boylan C.W., Colca J.R., Williamson J.R., Schlesinger P.H. Calcium and the malaria parasite: Parasite maturation and the loss of red cell deformability Blood Cells. 1991;17(1):229-241.
Easom R.A., Landt M., Colca J.R., Hughes J.H., Turk J., McDaniel M. Effects of insulin secretagogues on protein kinase C-catalyzed phosphorylation of an endogenous substrate in isolated pancreatic islets Journal of Biological Chemistry. 1990;265(25):14938-14946.
Hughes J.H., Colca J.R., Easom R.A., Turk J., McDaniel M.L. Interteukin 1 inhibits insulin secretion from isolated rat pancreatic islets by a process that requires gene transcription and mRNA translation Journal of Clinical Investigation. 1990;86(3):856-863.
McCroskey M.C., Palazuk B.J., Pierce-Ramsey P.A., Colca J.R., Pearson J.D. Insulin-like effects of histones H3 and H4 on isolated rat adipocytes BBA - Molecular Cell Research. 1989;1011(2-3):212-219.
Colca J., Wolf B., McDaniel M. Regulation of calcium uptake/efflux from the islet-cell endoplasmic reticulum with regard to the secretion of insulin. Progress in clinical and biological research. 1988;265:117-132.
Colca J., Wyse B., Sawada G., Jodelis K., Connell C., Fletcher-McGruder B., Palazuk B., Diani A. Ciglitazone, a hypoglycemic agent: Early effects on the pancreatic islets of ob ob mice Metabolism. 1988;37(3):276-280.
DeWald D., Colca J., McDonald J., Pearson J. Separation of tyrosine phosphorylated calmodulin from calmodulin using non-porous anion-exchange hplc Journal of Liquid Chromatography. 1988;11(9-10):2109-2120.
Laurino J.P., Colca J.R., Pearson J.D., Dewald D.B., McDonald J.M. The in vitro phosphorylation of calmodulin by the insulin receptor tyrosine kinase Archives of Biochemistry and Biophysics. 1988;265(1):8-21.
McCroskey M., R. Colca J., D. Pearson J. Determination of [<sup>32</sup>P]Phosphoamino acids in protein hydrolysates by isocratic anion-exchange high-performance liquid chromatography Journal of Chromatography A. 1988;442(C):307-315.
Wolf B.A., Colca J.R., Turk J., Florholmen J., McDaniel M.L. Regulation of Ca<sup>2+</sup> homeostasis by islet endoplasmic reticulum and its role in insulin secretion American Journal of Physiology - Endocrinology and Metabolism. 1988;254(2 Pt 1)
Colca J.R., DeWald D.B., Pearson J.D., Palazuk B.J., Laurino J.P., McDonald J.M. Insulin stimulates the phosphorylation of calmodulin in intact adipocytes Journal of Biological Chemistry. 1987;262(24):11399-11402.
Wolf B., Florholmen J., Colca J., McDaniel M. GTP mobilization of Ca<sup>2+</sup> from the endoplasmic reticulum of islets. Comparison with myo-inositol 1,4,5-trisphosphate Biochemical Journal. 1987;242(1):137-141.
McDONALD J.M., PERSHADSINGH H.A., COLCA J. The Role of Calcium and Calmodulin in Insulin Receptor Function in the Adipocyte Annals of the New York Academy of Sciences. 1986;488(1):406-418.
Wolf B., Colca J., McDaniel M. Calmodulin inhibits inositol trisphosphate-induced Ca<sup>2+</sup> mobilization from the endoplasmic reticulum of islets Biochemical and Biophysical Research Communications. 1986;141(2):418-425.
Wolf B.A., Colca J.R., Comens P.G., Turk J., McDaniel M.L. Glucose 6-phosphate regulates Ca<sup>2+</sup> steady state in endoplasmic reticulum of islets. A possible link in glucose-induced insulin secretion Journal of Biological Chemistry. 1986;261(35):16284-16287.
Colca J., Wolf B., Comens P., McDaniel M. Protein phosphorylation in permeabilized pancreatic islet cells Biochemical Journal. 1985;228(3):529-536.
Kotagal N., Colca J., Buscetto D., McDaniel M. Effect of insulin secretagogues and potential modulators of secretion on a plasma membrane (Ca<sup>2+</sup> + Mg<sup>2+</sup>)-ATPase activity in islets of langerhans Archives of Biochemistry and Biophysics. 1985;238(1):161-169.
Turk J., Colca J., McDaniel M. Arachidonic acid metabolism in isolated pancreatic islets. III. Effects of exogenous lipoxygenase products and inhibitors on insulin secretion Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism. 1985;834(1):23-36.
Turk J., Colca J., McDaniel M. Arachidonic acid metabolism in isolated pancreatic islets. IV. Negative ion-mass spectrometric quantitation of monooxygenase product synthesis by liver and islets Biochimica et Biophysica Acta - Lipids and Lipid Metabolism. 1985;835(1):1-17.
Turk J., Wolf B., Comens P., Colca J., Jakschik B., McDaniel M. Arachidonic acid metabolism in isolated pancreatic islets. IV. Negative ion-mass spectrometric quantitation of monooxygenase product synthesis by liver and islets Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism. 1985;835(1):1-17.
Colca J., Kotagal N., Lacy P., Brooks C., Norling L., Landt M., McDaniel M. Glucose-stimulated protein phosphorylation in the pancreatic islet Biochemical Journal. 1984;220(2):529-537.
Colca J., McDaniel M. Glucose-stimulated protein phosphorylation in the pancreatic islet Federation Proceedings. 1984;43(7)
Norling L., Colca J., Brooks C., Kloepper R., McDaniel M., Landt M. Specificity of inhibition of calcium- and calmodulin-dependent protein kinase by alloxan BBA - General Subjects. 1984;801(2):197-205.
Turk J., Colca J., Kotagal N., McDaniel M. Arachidonic acid metabolism in isolated pancreatic islets. I. Identification and quantitation of lipoxygenase and cyclooxygenase products Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism. 1984;794(1):110-124.
Turk J., Colca J., Kotagal N., McDaniel M. Arachidonic acid metabolism in isolated pancreatic islets. II. The effects of glucose and of inhibitors of arachidonate metabolism on insulin secretion and metabolite synthesis Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism. 1984;794(1):125-136.
Colca J., Brooks C., Landt M., McDaniel M. Correlation of Ca<sup>2+</sup>- and calmodulin-dependent protein kinase activity with secretion of insulin from islets of Langerhans Biochemical Journal. 1983;212(3):819-827.
Colca J., Kotagal N., Lacy P., McDaniel M. Modulation of active Ca<sup>2+</sup> uptake by the islet-cell endoplasmic reticulum Biochemical Journal. 1983;212(1):113-121.
Colca J.R., Kotagal N., Brooks C.L. Alloxan inhibition of a Ca<sup>2+</sup>- and calmodulin-dependent protein kinase activity in pancreatic islets Journal of Biological Chemistry. 1983;258(12):7260-7263.
Colca J.R., Kotagal N., Lacy P.E., McDaniel M.L. Comparison of the properties of active Ca<sup>2+</sup> transport by the islet-cell endoplasmic reticulum and plasma membrane BBA - Biomembranes. 1983;729(2):176-184.
Kaplan D., Colca J., McDaniel M. Insulin as a surface marker on isolated cells from rat pancreatic islets. The Journal of cell biology. 1983;97(2):433-437.
Kotagal N., Colca J.R., McDaniel M.L. Activation of an islet cell plasma membrane (Ca<sup>2</sup> + Mg<sup>2+</sup>)-ATPase by calmodulin and Ca-EGTA Journal of Biological Chemistry. 1983;258(8):4808-4813.
McDaniel M., Colca J., Kotagal N., Lacy P. A Subcellular Fractionation Approach for Studying Insulin Release Mechanisms and Calcium Metabolism in Islets of Langerhans Methods in Enzymology. 1983;98(C):182-200.
Colca J.R., Hazelwood R.L. Amino acids as in vitro secretogogues of avian pancreatic polypeptide (APP) and insulin from the chicken pancreas General and Comparative Endocrinology. 1982;47(1):104-110.
Colca J.R., Hazelwood R.L. Persistence of immunoreactive insulin, glucagon and pancreatic polypeptide in the plasma of depancreatized chickens Journal of Endocrinology. 1982;92(3):317-326.
Colca J.R., McDonald J.M., Kotagal N., Patke C., Fink C.J., Greider M.H., Lacy P.E., McDaniel M.L. Active calcium uptake by islet-cell endoplasmic reticulum. Journal of Biological Chemistry. 1982;257(12):7223-7228.
Kotagal N., Patke C., Landt M., McDonald J., Colca J., Lacy P., McDaniel M. Regulation of pancreatic islet-cell plasma membrane Ca<sup>2+</sup> + Mg<sup>2+</sup>-ATPase by Calmodulin FEBS Letters. 1982;137(2):249-252.
Landt M., McDaniel M.L., Bry C.G., Kotagal N., Colca J.R., Lacy P.E., McDonald J.M. Calmodulin-activated protein kinase activity in rat pancreatic islet cell membranes Archives of Biochemistry and Biophysics. 1982;213(1):148-154.
Colca J.R., Hazelwood R.L. Insulin, pancreatic polypeptide, and glucagon release from the chicken pancreas in vitro: Responses to changes in medium glucose and free fatty acid content General and Comparative Endocrinology. 1981;45(4):482-490.
Colca J.R., Hazelwood R.L. Pancreatectomy in the chicken: Does an extra-pancreatic source of insulin exist? General and Comparative Endocrinology. 1976;28(2):151-162.